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casian female who was evaluated by hema-
tology oncology for further work up and
management of her chronic but progressive anemia.
She reported weight loss, poor appetite, fatigue, nau-
sea, several episodes of non-bloody diarrhea and in-
creased abdominal girth over the past 3 months. On
admission, her hemoglobin was 8.9 gm/dL, platelets
were 43 k/mcl, WBC was 5.49 K/mcl with absolute
neutrophil count of 3.73 k/mcl and 0% peripheral
blasts. Her metabolic panel was abnormal for elevated
LDH (245 U/L) and alkaline phosphatase (207 U/L).
Her liver function tests were normal except for albu-
min of 2.5 g/dl. Computed tomography (CT) of the
abdomen/pelvis showed splenomegaly, ascites, and
retroperitoneal lymphadenopathy, a concern for a
lymphoproliferative or metastatic disease.
A bone marrow biopsy and aspirate performed to
determine the cause of her progressive anemia and
thrombocytopenia revealed hypercellularity (90%)
and increased blasts (35% on the touch preparation).
The blasts had scant cytoplasm and ﬁne chromatin
(blue arrows in Figure 1). In addition, there were
paratrabecular inﬁltrates of round to spindled mast
cells (red arrow in Figure 1), which by immunohisto-
chemistry were strongly positive for tryptase (shown
in Figure 2), CD117, CD68 and CD25. The blasts
were weakly positive for CD117 and strongly positive
for myeloperoxidase, CD56, Bcl-2, and CD43 (not
shown). The aspirate was severely hemodiluted, likely
due to the reticulin ﬁbrosis observed in the biopsy.
Flow cytometry specimen was also hemodiluted (9%blasts) with the following myeloid immunophenotype:
CD33 positive CD13 positive CD56 positive CD117
partially positive CD34 negative HLA-DR negative.
Based on these ﬁndings the patient was diagnosed
with AML and SM, a subset of systemic mastocytosis
with associated clonal hematologic non-mast cell line-
age disease (SM-AHNMD).
The patient’s diarrhea responded brieﬂy to antimo-
tility agent loperamide, but while awaiting deﬁnitive
treatment plan, her symptoms worsened rapidly and re-
quired admission for severe, profuse non-bloody diar-
rhea, dehydration and abdominal distension.
Splenomegaly and ascites were noted on clinical exam.
Labs continued to show anemia and thrombocytopenia.
Initial test was positive for clostridium difﬁcile (C. diff).
This was successfully treated with metronidazole and
then with oral vancomycin. Subsequent tests for C. diff,
other infectious agents and transglutaminase IgA anti-
body were negative. However, the patient continued
to have multiple episodes of diarrhea with little relief
from antimotility agents. Diarrhea was deemed second-
ary to SM. Extensive work up for portal hypertension
was non-diagnostic. She could not undergo colonoscopy
and liver biopsy due to thrombocytopenia. As a consid-
eration for treatment with imatinib she was tested for
BCR/ABL and PDGFRA fusion genes which were
negative. KIT mutation analysis could not be per-
formed due to lack of tissue sample. After a lengthy dis-
cussion with the patient regarding various options of
treatment, she chose palliative care and hospice. How-
ever, severe diarrhea limited her transition to hospice;
she was then started on a trial of octreotide every 8 h
for her diarrhea. She had a rapid response with dra-Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
Figure 1. Hypercellular marrow with blasts (blue arrows) and paratrabecular infiltrates of mast cells (red arrows). (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article.)
Figure 2. Intense staining by foci of mast cell infiltrates by tryptase (red arrows). (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.)
OCTREOTIDE FOR RELIEF OF (GI) SYMPTOMS case reportmatic improvement in her diarrhea symptoms and was
appropriately transitioned to inpatient hospice care.DISCUSSION
Diagnosis of SM cannot be based on clinical ﬁndings
alone; therefore, bone marrow biopsy remains the cor-
nerstone for conﬁrming suspicion of the disease. One
major and at least one minor criterion or three minor
criteria must be satisﬁed in order to make the diagno-
sis based upon the World Health Organization
(WHO) guidelines shown in Table 11–3.
WHO divides SM into several categories, of which
SM-AHNMD is one. Any AHNMD discovered in
the presence of SM must be considered secondary
to SM as opposed to de novo. Stratiﬁed as high-risk
AML, the majority of patients are treated withHematol Oncol Stem Cell Ther 6(2) Second Quarter 2013high-dose chemotherapy and stem cell transplant.
To diagnose the two ailments concurrently requires
WHO criteria to be met for both SM and AHNMD
separately. More often in AML, the KIT mutation is
present only on mast cells leaving blast cells vacant of
the mutation, as opposed to other SM-AHNMD
which may illustrate the mutant on both mast and
blast cells4. Median survival usually ranges from 11–
24 months5,6. Poor prognostic factors include: (1)
age 65; (2) anemia and thrombocytopenia; (3)
weight loss and hypoalbuminemia; and (4) excess
bone marrow blast cells (>5%)5.
Differential diagnoses for the patient’s diarrhea in-
clude other reasons for mast cell hyperplasia within
the bone marrow like myelodysplastic syndromes,
Hodgkin’s and non-Hodgkin’s lymphoma. The mast
cell morphology in these cases would be normal with-73
Table 1. WHO diagnostic criteria for systemic mastocytosis (modified from Valent et al.)3.
Major criterion Multifocal dense infiltrates of mast cells (>15 mast cells in aggregates) in bone marrow biopsies and/or in sections of
other extracutaneous organ(s)
Minor criterion (a) >25% of all mast cells are atypical cells on bone marrow smears or are spindle-shaped in mast cell infiltrates
detected on sections of visceral organs.
(b) C-kit point mutation at codon 816 in the bone marrow or other extracutaneous organ.
(c) Mast cells in bone marrow or blood or another extracutaneous organ express CD2 or/and CD25.
(d) Serum tryptase concentration >20 ng/ml (this criterion only valid if an unrelated myeloid neoplasm has been
excluded).
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would display normal immunophenotypes lacking
CD2 and CD252,7,8.
Zollinger-Ellison (ZE), carcinoid syndrome, and
VIPoma are additional considerations for the cause
of her diarrhea. These disorders present with ﬂushing
associated with sweating and absence of rash, hepato-
splenomegaly. In SM, pigmentosa urticaria is com-
mon and hepatosplenomegaly can be seen in 20% of
patients. VIPoma is diagnosed via vasoactive intesti-
nal polypeptide (VIP) levels, ZE presents with gas-
trinemia, and urinary 5-hydroxyindoleacetic acid
(5HIAA) is seen with carcinoid syndrome. These lev-
els are all normal in SM9.
Management of SM remains intricate. Several
studies have shown promising data with regard to cur-
ing the disease, but treatment frequently remains
symptomatic due to the refractory nature of the mast
cells to most conventional antineoplastic agents4. GI
symptoms are present in anywhere from 60–80% of
SM cases9. Abdominal pain affects approximately half
of those with GI complaints, while diarrhea is com-
mon in 40%. Nausea and vomiting occur in 30% of
these cases7,9. While the majority of these symptoms
are non-lethal, they are capable of severely affecting
patients’ quality of life.
Interferon-alfa provides relief of numerous symp-
toms, but it is poorly tolerated and long-term therapy
is required5,10. Cladribine (2-chlorodeocyadenosine)
recently showed promise as an effective cytoreductive
agent providing a rapid decrease of mast cell inﬁltra-
tion and activation as well as symptomatic relief.
But bone marrow suppression and mutagenic effects
were the main adverse effects of cladribine10. The
KIT mutation plays a signiﬁcant role in treatment
as the AML blast cell KIT mutant confers resistance
to certain drugs, such as imatinib4.
Symptomatic treatment historically involves H1 and
H2 histamine receptor blockers, ketotifen, cromolyn so-
dium, and anti-leukotriene drugs2. Antihistamines re-
lieve symptoms of ﬂushing and pruritus and, bydecreasing gastric acid secretion, reduce diarrhea and
abdominal cramping. Sodium cromolyn inhibits degra-
dation of mast cells thus reducing the amount of media-
tors released and improving GI symptoms, especially
diarrhea. Montelukast has been shown to relieve pruri-
tus and ﬂushing but may increase abdominal cramping7.
Budesonide and other oral corticosteroids have proven
effective in relieving abdominal pain and diarrhea9.
Our patient was treated with 50 mcg intravenous
octreotide every 8 h due to the unavailability of oral so-
dium cromolyn at our facility and her concurrent AML
precluded the use of corticosteroids for fear of further
weakening her immune system. Octreotide provided
signiﬁcant symptomatic relief from diarrhea and greatly
improved her quality of life. Only one other study was
found to have attempted the use of octreotide in symp-
tomatic relief of SM. Octreotide and total parental
nutrition were successfully utilized to treat the patient’s
diarrhea and malnutrition due to SM11.
Octreotide is a somatostatin analog, working by
inhibiting serotonin release, secretion of gastrin,
VIP and other hormones; it also decreases the rate
of gastric emptying, smooth muscle contractions and
splanchnic blood ﬂow12. It is indicated for diarrhea
associated with VIPomas and carcinoid tumors as
well as unlabeled uses for diarrhea resulting from che-
motherapy and graft versus host disease. As a result of
these two cases and octreotide’s proven beneﬁt in
other conditions associated with signiﬁcant diarrhea,
we promote the option of octreotide as a viable alter-
native in the case of unavailability of sodium cromolyn
and inability to use corticosteroids.
Further studies are highly recommended on the
effective nature of this drug for its use in patients with
SM. Comparison studies should be done to determine
if it is as effective, or possibly more effective, in pre-
venting or reducing diarrhea associated with SM.
Limitations on this report include the age, medical
comorbidities and complication with C. diff colitis
and its possible effect on the course of our patient’s
diarrhea.Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
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